Tool: DupCheckTool: DupCheck is a web-based tool to screen for duplicate patients in clinical trials within and across studies, sponsors and therapeutic areas. Please visit our "Tools" page for more information.

Project FlyerProject Flyer

Click here to download 
the NEWMEDS project flyer! 

consortium teaser

Project Office Project Office Annual PGB and WP Leads Meetings Annual PGB and WP Leads Meetings Project Governance Project Governance Funding Mechanisms Funding Mechanisms

  Members Area

IMI | The Innovative Medicines Initiative
EFPIA | European Federation of Pharmaceutical Industries and Associations

logo Eli Lilly

Eli Lilly and Co Ltd
Erl Wood Manor, Sunninghill Road
GU20 6PH
Windlesham, Surrey,

Eli Lilly

Participant's Lead

Mark Tricklebank
Director, Senior Research Fellow - behavioural neuroscience and pharmacology 
E-Mail to Mark Tricklebank Contact  

Institute Presentation

Lilly is a global pharmaceutical company with active programs in Psychiatry areas relevant to this project. Lilly’s commitment to neuroscience is shown by the contribution the company has made to treatments for depression (Prozac, Cymbalta), ADHD (Straterra) and schizophrenia (zyprexa and the revolutionary mGlu2/3 agonists). A number of disease-modifying approaches are currently being tested in the clinic for Alzheimer’s patients. Collaboration is a key plank in the evolving strategy of the company. In the realm of cognition, the Lilly Centre for Cognitive Neuroscience has recently been established as an industrial-academic consortium and post-doctoral fellowship programme focussed on improving animal assays and disease models for the discovery of drugs to treat cognitive impairment associated with cognitive dysfunction. Lilly personnel thus have great expertise in a number of areas that will support this project.

12 Eli Lilly and Company Ltd